Literature DB >> 31119944

Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project.

Matthew A Spinelli1, David V Glidden2, Peter L Anderson3, Monica Gandhi1, Vanessa M McMahan4, Patricia Defechereux5, Mauro Schechter6, Valdiléa G Veloso7, Suwat Chariyalertsak8, Juan V Guanira9, Linda-Gail Bekker10, Susan P Buchbinder5, Robert M Grant5.   

Abstract

Bone mineral density (BMD) declines due to tenofovir-containing pre-exposure prophylaxis (PrEP) have varied among PrEP demonstration projects, potentially related to variable adherence. Characterization of BMD changes in highly adherent individuals, estimated via tenofovir-diphosphate (TFV-DP) levels in dried blood spots (DBS), can assist clinicians when counseling patients. Cisgender men who have sex with men and transwomen in the optional dual-energy X-ray absorptiometry (DXA) substudy of a large, international, open-label PrEP demonstration project, the iPrEx-open-label extension (OLE) study underwent DXA scans and DBS collection every 24 weeks, with average weekly dosing adherence patterns (2, 4, and 7 doses/week) estimated from validated TFV-DP cut-offs. The mean percent BMD change was estimated in strata of average weekly adherence by using a linear mixed-effects model to calculate the BMD decline in highly adherent individuals on PrEP for the first time. DXA/DBS data were available for 254 individuals over a median of 24 weeks in iPrEx-OLE from June 2011 to December 2013. The percent decline in spine BMD was monotonically associated with strata of increasing average weekly adherence (p < .001 trend); the p value for trends using hip BMD measurements was .07. Individuals with estimated daily adherence experienced a 1.2% decrease in spine BMD and a 0.5% drop in hip BMD. In highly adherent PrEP users, we found a lower-than-expected drop in BMD when compared with previous studies. This drop is likely not clinically significant for most PrEP users. However, for those at the highest risk of fracture who plan prolonged PrEP use, alternate PrEP strategies could be considered.

Entities:  

Keywords:  PrEP; adherence; bone mineral density; cohort studies; men who have sex with men; transgender people

Mesh:

Substances:

Year:  2019        PMID: 31119944      PMCID: PMC6735322          DOI: 10.1089/AID.2018.0297

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  34 in total

1.  Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.

Authors:  Roger Bedimo; Naim M Maalouf; Song Zhang; Henning Drechsler; Pablo Tebas
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

2.  Prevalence of low bone mineral density in men and women infected with human immunodeficiency virus 1 and a proposal for screening strategy.

Authors:  Murielle Mary-Krause; Jean-Paul Viard; Béatrice Ename-Mkoumazok; Michelle Bentata; Marc-Antoine Valantin; Pascale Missy; Iuliana Darasteanu; Christian Roux; Sami Kolta; Dominique Costagliola; Sylvie Rozenberg
Journal:  J Clin Densitom       Date:  2012-07-21       Impact factor: 2.617

3.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

4.  Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients.

Authors:  Michelle K Yong; Julian H Elliott; Ian J Woolley; Jennifer F Hoy
Journal:  J Acquir Immune Defic Syndr       Date:  2011-07-01       Impact factor: 3.731

5.  Alcohol intake as a risk factor for fracture.

Authors:  John A Kanis; Helena Johansson; Olof Johnell; Anders Oden; Chris De Laet; John A Eisman; Huibert Pols; Alan Tenenhouse
Journal:  Osteoporos Int       Date:  2004-09-29       Impact factor: 4.507

6.  Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population.

Authors:  Linda M Mundy; Ada O Youk; Grace A McComsey; Steve J Bowlin
Journal:  AIDS       Date:  2012-06-01       Impact factor: 4.632

7.  Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco.

Authors:  Albert Y Liu; Eric Vittinghoff; Deborah E Sellmeyer; Risha Irvin; Kathleen Mulligan; Kenneth Mayer; Melanie Thompson; Robert Grant; Sonal Pathak; Brandon O'Hara; Roman Gvetadze; Kata Chillag; Lisa Grohskopf; Susan P Buchbinder
Journal:  PLoS One       Date:  2011-08-29       Impact factor: 3.240

8.  Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy.

Authors:  Arash A Horizon; Robert J Joseph; Qiming Liao; Steven T Ross; Gary E Pakes
Journal:  HIV AIDS (Auckl)       Date:  2011-06-28

9.  Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.

Authors:  Gaudensia Mutua; Eduard Sanders; Peter Mugo; Omu Anzala; Jessica E Haberer; David Bangsberg; Burc Barin; James F Rooney; David Mark; Paramesh Chetty; Patricia Fast; Frances H Priddy
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

10.  Tenofovir-associated bone density loss.

Authors:  Iwen F Grigsby; Lan Pham; Louis M Mansky; Raj Gopalakrishnan; Kim C Mansky
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

View more
  3 in total

Review 1.  HIV Pre-exposure Prophylaxis and Its Impact on the Gut Microbiome in Men Having Sex With Men.

Authors:  Nicola Luigi Bragazzi; Rola Khamisy-Farah; Christina Tsigalou; Naim Mahroum
Journal:  Front Microbiol       Date:  2022-06-23       Impact factor: 6.064

2.  Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305.

Authors:  Todd T Brown; Krista Yuhas; Kenneth H Mayer; Raphael J Landovitz; Mark A Marzinke; Craig W Hendrix; Ying Q Chen; Karen L Klingman; Wairimu Chege; Marybeth B Mccauley; Roy M Gulick; Timothy J Wilkin
Journal:  J Antimicrob Chemother       Date:  2022-02-02       Impact factor: 5.758

3.  A Pharmacist-Led, Same-Day, HIV Pre-Exposure Prophylaxis Initiation Program to Increase PrEP Uptake and Decrease Time to PrEP Initiation.

Authors:  Christine M Khosropour; Kandis V Backus; Arianna R Means; Laura Beauchamps; Kendra Johnson; Matthew R Golden; Leandro Mena
Journal:  AIDS Patient Care STDS       Date:  2020-01       Impact factor: 5.078

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.